SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 1117.
  • 2
    Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 165565.
  • 3
    Haworth SG. The management of pulmonary hypertension in children. Arch Dis Child 2008; 93: 6205.
  • 4
    Rosenzweig EB, Barst RJ. Pulmonary arterial hypertension in children: a medical update. Curr Opin Pediatr 2008; 20: 28893.
  • 5
    Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 3439.
  • 6
    Beghetti M, Hoeper MM, Kiely DG, Carlsen J, Schwierin B, Segal ES, Humbert M. Safety experience with bosentan in 146 children 2–11 years with pulmonary arterial hypertension: results from the European post-marketing surveillance program. Pediatr Res 2008; 64: 2004.
  • 7
    Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, Levy PC, Reid LM, Vreim CE, Williams GW. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 21623.
  • 8
    Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension. N Engl J Med 2004; 351: 142536.
  • 9
    Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, Barst RJ. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697704.
  • 10
    Lammers A, Hislop A, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007; 93: 73943.
  • 11
    Dingemanse J, Van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43: 1089115.
  • 12
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Tripartite Harmonised Guideline. Clinical Investigation of Medicinal Products in the Pediatric Population, E11. Fed Regist 2000; 65: 1977781.
  • 13
    Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, Van Giersbergen PLM. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 37282.
  • 14
    Dell D, Lausecker B, Hopfgartner G, Van Giersbergen PLM, Dingemanse J. Evolving bioanalytical methods for the cardiovascular drug bosentan. Chromatographia 2002; 55 (Suppl.): S1159.
  • 15
    Turner-Bowker DM, Bayliss MS, Kosinski M, Zhao J, Saris-Baglama RN. SF-10 for Children™: A User's Guide. Lincoln, RI: QualityMetric Incorporated, 2003.
  • 16
    Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1976.
  • 17
    Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, Van Marle S, Viischer HW, Jonkman JH. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 1999; 39: 70314.
  • 18
    Dingemanse J, Bodin F, Weidekamm E, Kutz K, Van Giersbergen P. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2002; 42: 2839.
  • 19
    Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 111923.
  • 20
    Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 66470.
  • 21
    Summary of Product Characteristics Tracleer®. Actelion Pharmaceuticals Ltd., 15 May 2007.
  • 22
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896903.